GlassScriptPhysician profile
Chase K Sovell
NPI 1184674301
$5,392.69
in general payments reported to CMS, 2019-2025
36 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $233 · 2021: $484 · 2022: $641 · 2023: $976 · 2024: $1,713 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,572 · Travel and Lodging: $1,165 · Education: $35.06 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,572.07 |
| Travel and Lodging | $1,165.09 |
| Education | $35.06 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,583.37 | 2024-2025 | |
| Coloplast Corp | $683.58 | 2019-2025 | Speedicath |
| Axonics, INC. | $366.32 | 2022-2024 | Axonics |
| Srs Medical Systems, INC. | $292.61 | 2021-2022 | |
| Olympus America INC. | $263.09 | 2021-2024 | Itind System |
| Accord Healthcare, INC. | $199.32 | 2022-2024 | |
| Teleflex LLC | $191.36 | 2022-2023 | Urolift |
| Antares Pharma, INC. | $176.61 | 2019-2024 | Xyosted |
| Medtronic USA, INC. | $143.94 | 2020 | |
| Conmed Corporation | $138.08 | 2023 | Airseal |
| Agiliti Surgical, INC. | $129.61 | 2023 | Sonablate |
| Dendreon Pharmaceuticals LLC | $115.47 | 2022-2024 | Provenge |
| Abbvie INC. | $96.36 | 2020-2025 | Botox |
| Merck Sharp & Dohme LLC | $95.32 | 2021-2025 | Lynparza, Keytruda, Welireg |
| Progenics Pharmaceuticals, INC. | $76.24 | 2022-2025 | Pylarify |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $75.70 | 2023 | Aquabeam Robotic System |
| Cook Medical LLC | $72.97 | 2024-2025 | Cook, Litho 150 |
| Halozyme INC | $71.86 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $60.00 | 2022 | |
| Ethicon US, LLC | $58.44 | 2022-2023 | Monocryl, Dermabond Prineo, Echelon Flex |
| 180 Medical, INC. | $58.42 | 2020-2023 | Gentlecath Glide |
| Astellas Pharma US INC | $52.57 | 2019-2022 | |
| Hitachi Healthcare Americas Corp. | $52.33 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $51.91 | 2023-2025 | Imfinzi |
| Telix Pharmaceuticals | $48.46 | 2024 | Illuccix |
| Novartis Pharmaceuticals Corporation | $47.31 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $39.44 | 2019-2025 | Adstiladrin |
| Tolmar, INC. | $30.02 | 2024 | |
| Convatec INC. | $23.82 | 2023 | |
| Allergan, INC. | $21.25 | 2019 | |
| Blue Earth Diagnostics | $14.46 | 2025 | Posluma |
| Boston Scientific Corporation | $13.80 | 2021 | |
| Ambu INC. | $12.85 | 2020 | |
| Urovant Sciences INC | $12.18 | 2021 | |
| Janssen Biotech, INC. | $12.00 | 2024 | Erleada |
| Neotract INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Sovell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.